Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification

Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recen...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2004-03, Vol.109 (8), p.990-996
Main Authors: CAMM, A. John, PRATT, Craig M, SCHWARTZ, Peter J, AL-KHALIDI, Hussein R, SPYT, Maria J, HOLROYDE, Michael J, KARAM, Roger, SONNENBLICK, Edmund H, BRUM, Jose M. G
Format: Article
Language:English
Subjects:
Aged
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - therapeutic use
Arrhythmias, Cardiac - etiology
Arrhythmias, Cardiac - mortality
Arrhythmias, Cardiac - prevention & control
Atrial Fibrillation - etiology
Atrial Fibrillation - prevention & control
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Double-Blind Method
Female
Heart Rate
Humans
Hydantoins
Imidazoles - adverse effects
Imidazoles - therapeutic use
Imidazolidines
Life Tables
Male
Medical sciences
Middle Aged
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Myocardial Infarction - physiopathology
Neutropenia - chemically induced
Piperazines - adverse effects
Piperazines - therapeutic use
Potassium Channel Blockers - adverse effects
Potassium Channel Blockers - therapeutic use
Risk Factors
Survival Analysis
Torsades de Pointes - etiology
Torsades de Pointes - prevention & control
Treatment Outcome
Ventricular Dysfunction, Left - drug therapy
Ventricular Dysfunction, Left - etiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.0000117090.01718.2A